News
Public · Published
CVS Health Corporation Stock 12‑Month Price Target Cut to $113.25, Implies 24% Upside
The average 12-month price target for CVS Health Corporation fell from $113.88 to $113.25, based on estimates from 24 analysts. Using the Nov. 3 closing price, the new target implies approximately 24% potential upside; the consensus rating remains Buy among 30 analysts.
Published:
Updated:
What happened
The average 12-month price target for CVS Health Corporation fell from $113.88 to $113.25, based on estimates from 24 analysts. Using the Nov. 3 closing price, the new target implies approximately 24% potential upside; the consensus rating remains Buy among 30 analysts.
Confirmed
Global impact / market context
A lower target signals that analysts have modestly reduced their expected value for CVS shares, which may influence investor expectations and buying decisions. The stated upside still compares the new target with the Nov. 3 closing price, not a guaranteed return or forecast of future performance.
Analyst inference
Analyst views remain broadly positive: 27 of 30 covering analysts rate CVS Buy, three rate it Hold, and none rate it Sell. However, the average target is lower, and individual forecasts span $101 to $123 per share, showing differing expectations.
Confirmed
What to watch
- Watch for future analyst target revisions and changes in the Buy, Hold, and Sell counts; these could shift investor expectations even if the company reports no new results. Analyst inference
- Compare the next average target with the current share price and the Nov. 3 reference price, since the reported 24% potential upside depends on that price comparison. Analyst inference
- The supplied information reports analyst estimates and ratings only; it gives no company results, business changes, or explanation for why the average target was reduced. Confirmed
Evidence
- Original source link unavailable